Cipla Q2 FY2023 Investor Presentation

Cipla's Q2 FY2023 investor presentation highlights strong revenue growth of 6% YoY (12% ex-covid) driven by One-India momentum and differentiated North America portfolio including Lenalidomide launch. The company achieved overall revenue of INR 5,829 Cr with adjusted EBITDA margin of 22.3% and maintained robust traction across core therapeutic areas and business segments.